NewsTuesday, 26. March 2013
VORTEX convincingly delivers excellent Aerosol Performance
The in-vitro aerosol performance of three small volume valved holding chambers (VHC): VORTEX (PARI GmbH), AeroChamber Plus Z Stat (ACP; Trudell Medical International) und Able Spacer™ (AS; Clement Clarke International Ltd) was compared by Prof. J.-C. Dubus and his team from France. The pMDI used in the study was a combination of the corticosteroid beclomethasone dipropionate (BDP; 100 µg/dose) and the long-acting β-adrenergic bronchodilator formoterol (FMT; 6 µg/dose) (Innovair; Chiesi Farmaceutici S.p.A.). The Next Generation Impactor (NGI) was used to evaluate the dose of both active substances delivered by the pMDI alone as well as in combination with all three valved holding chamber tested. The distribution in particle size was measured also.
As expected, all three VHCs clearly reduced the throat deposition. In comparison to AeroChamber and Able Spacer™, VORTEX furthermore delivered a significantly higher delivered dose(Fig. 1; p<0.05) and fine particle dose (Fig. 2; p<0.05). At the same time it was VORTEX that retained the lowest quantity of both drugs in the chamber (p<0.01).
Fig. 1: Dose of beclomethasone aerosol delivered by a pMDI alone and in combination with three different VHCs.
Fig. 2: Influence of different VHCs on the fine particle dose (FPD) of beclomethasone aerosol.
These findings led the authors to conclude that among the three tested VHCs, it is VORTEX that provides the highest percentage of respirable particles, the highest delivered dose whilst at the same time retaining the lowest amount of medication in the device. VORTEX is therefore the VHC best suited to effectively deliver the tested drug combination.
Source: Goncalves TM et al. 2012; J Aerosol Med Pulm Drug Deliv. [Epub Oct 24]